Business Description
HilleVax Inc
NAICS : 541714
SIC : 2834
75 State Street, Suite 100 - 9995, Boston, MA, USA, 02109
Description
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | -0.79 | |||||
| Debt-to-Equity | -1.57 | |||||
| Debt-to-EBITDA | -1.59 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.71 | |||||
| 9-Day RSI | 55.17 | |||||
| 14-Day RSI | 53.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.55 | |||||
| Quick Ratio | 0.55 | |||||
| Cash Ratio | 0.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -160.43 | |||||
| ROIC % | -14.32 | |||||
| ROC (Joel Greenblatt) % | -43101.3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -5.06 | |||||
| EV-to-EBITDA | -5.06 | |||||
| EV-to-FCF | -50.43 | |||||
| Earnings Yield (Greenblatt) % | -19.78 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:HLVX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -3.28 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 53.74 | ||
| 14-Day ATR ($) | 1.252254 | ||
| 20-Day SMA ($) | 12.8695 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 7.9 - 20.95 | ||
| Shares Outstanding (Mil) | 33.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HilleVax Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||